

FORM PTO-1449
INFORMATION DISCLOSURE STATEMENT

Docket No.: HX96 [REDACTED] Sheet 1 of 2
Div

Serial No.: [REDACTED] Group: 1615

Applicant: Ismat Ullah et al

Filing Date: [REDACTED]

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Sub-class	Filing Date
<i>J</i>	AA	5227202	7/1993	Hodges et al.	424	462	
<i>J</i>	AB	5238686	8/1993	Eichel et al.	424	461	
	AC	H1286	2/1994	Eisman et al.	514	423	
	AD						

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Country	Class	Sub-class	Filing Date
<i>J</i>	AE	WO93/13801	22.07.93	PCT			
<i>J</i>	AF	WO98/11896	26.03.98	PCT			
	AG						

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

<i>J</i>	AH	Revue Medicale de Liege, 1996, 51/10 (668-669)
	AI	"Pravastatin's MI preventive effect, carvedilol's mortality benefit are among top newsmaker", Formulary, Vol. 31, Jan. 1998, 65-68.
	AJ	Veinot, J.P. et al, "The effects of lovastatin on neointimal hyperplasia following injury in a porcine coronary artery model", Can. J. Cardiol. Vol. 12(1), 65-70.
	AK	Bjelajac, A. et al, "Prevention and Regression of Atherosclerosis: Effects of HMG-CoA Reductase Inhibitors", Ann. Pharmacother., 30, No. 11, 1996, 1304-15.
	AL	Pedersen, T.R. et al, "Safety and Tolerability of Cholesterol Lowering With Simvastatin During 5 Years in the Scandinavian Simvastatin Survival Study", Arch. Intern. Med., Vol 156, No. 18, 1996, 2085-92.
	AM	Sacks, F.M. et al, "The Effect of Pravastatin on Coronary Events After Myocardial Infarction in Patients with Average Cholesterol Levels", N. Engl. J. Med. 335, No. 14, 1001-09, 1996.
	AN	J. Am. Coll. Cardiol. 27, No. 2, Suppl. A, 413A, 1996.
	AO	Biorheology, Vol. 32, No2. 2-3, 1995, 264
	AP	American Family Physician, 1995, 52/3, (761, 766, 768, 775).
	AQ	Circulation, 92, No. 8, Suppl. I-196, 1995.
	AR	Pitt, B. et al, "Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC I): Reduction in Atherosclerosis Progression and Clinical Events", JACC Vol. 26, No. 5, 1995, 1133-39.
	AS	Watts, G.R., "Simvastatin decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: pathophysiological and therapeutic implications", Eur. J. Clin. Invest. 25, No. 8, 559-67, 1995.
	AT	Sacks, F.M. et al, "Baseline Characteristics in the Cholesterol and Recurrent Events (CARE) Trial of Secondary Prevention in Patients With Average Serum Cholesterol Levels", Amer. J. of Cardiology, 1995, 75/8, 621-623.
	AU	Brown, G. et al, "Regression of Coronary Artery Disease as a Result of Intensive Lipid-Lowering Therapy in Men with High Levels of Apolipoprotein B", N. Engl. J. Med. 323, No. 19, 1289-98, 1990.
	AV	Fawcett, J.P. et al, "Does Cholesterol Depletion Have Adverse Effects on Blood Rheology?", Angiology 45, No. 3, 199-206, 1994.
	AW	Pan, H.Y. "Clinical pharmacology of pravastatin, s selective inhibitor of HMG-CoA reductase", Eur. J. Clin. Pharmacol. 40, Suppl. 1, 515-518, 1991.
<i>3</i>	AX	Bo, M. et al, "One-Year Experience in the Treatment of Elderly Hypercholesterolemic Patients with Pravastatin", Curr. Ther. Res. 50, No. 2, 151-158, 1991.

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
INFORMATION DISCLOSURE STATEMENT

Docket No.: HX96 ~~XXXX~~ Sheet 2 of 2
Serial No.: ~~XXXXXX~~ Group: 1615
Applicant: Ismat Ullah et al
Filing Date: ~~XXXXXX~~

AY	Lancet 338, No. 8778, 1339, 1991.
AZ	Br. J. Haematol. 80, Supl 1, 35, 1992.
BA	J. Am. Col. Cardiol. 23, Feb. 1994:1A-484A, Spec. Issue 131A
BB	Egashira, K. et al, "Reduction in Serum Cholesterol With Pravastatin Improves Endothelium-Dependent Coronary Vasomotion in Patients With Hypercholesterolemia", Circulation 89, No. 6, 2519-24, 1994.

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609;
Draw line through citation if not in conformance and not considered. Include copy of this form with
next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
J	AA	H1286	2/1/94	Eisman et al.	—	—	
J	AB	5,225,202	7/6/93	Hodges et al.	—	—	
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

RECEIVED
OCT 08 2002
TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	WO97/38694	10/23/97	World (PCT as published)			<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	
	AS	
	AT	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.